Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer
ObjectiveThe current clinical data regarding the re-administration of PARPi maintenance therapy in platinum sensitive recurrent ovarian cancer (PSROC) is limited. This study aims to investigate the efficacy and associated factors of PARPi re-maintenance therapy in PSROC patients in China.MethodsIn t...
Saved in:
Main Authors: | Yulin Wang, Yunjie Yang, Binghong Guo, Xiaoyan Li, Renakezi Tuersun, Ye Cao, Jundong Li, Jihong Liu, Su Li, Tao Liu, Yongwen Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1512339/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Simultaneously delivery of functional gallium ions and hydrogen sulfide to endow potentiated treatment efficacy in chemo- and PARPi-resistant ovarian cancer
by: Sangsang Tang, et al.
Published: (2025-02-01) -
Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors
by: Romain Pacaud, et al.
Published: (2025-01-01) -
PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01) -
Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
by: Yinan Xiao, et al.
Published: (2025-01-01) -
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
by: Trudy J. Philips, et al.
Published: (2025-01-01)